Skip to content
Who we help

Finished deliverables, for every function in biopharma.

Product planning, competitive intelligence, forecasting, commercial, BD&L and scientific teams each hand the agent a different assignment. These are the starting set, and the agent can be pointed at whatever else your team builds by hand.

Premium evidence, met by an agent that knows biopharma.

01 · Evidence
Analyst consensus
Broker research
KOL transcripts
China coverage
Congresses
+ 9 source buckets
Licensed, entity-resolved to asset and trial.
02 · Orchestration
01 Plan the sections
02 Retrieve per claim
03 Reconcile conflicts
04 Verify against source
Runs against the deliverable’s known structure. Uncited claims are blocked, not softened.
03 · Output
.docx Reference list, reviewable structure
.pptx Your master, one argument per slide
.xlsx Live formulas, assumption cells, source notes
.html Interactive dashboards, open in a browser
Your forecaster drives the model instead of retyping it.

What the Agent builds.

Illustrative

Target Product Profile

DOCX · PPTX
New product planningScientific & clinical

Target values with the readout behind each, and a history of what moved.

Attribute
Target
Comp A
Comp B
ORR
≥ 45% [1]
38.1%
32.6%
mPFS
≥ 11.0 [2]
9.4
7.1
Gr ≥3
≤ 30% [3]
34.9%
41.2%
v14 mPFS bar raised 9.5 → 11.0 mo

Disease & Drug Analogs

XLSX · PPTX
ForecastingSearch & evaluate · BD&L

Precedents picked on stated criteria — and the curves they actually produced.

launch +8 quarters
— Analog A · 31% peak — B · 22% — C · 14%

Patient Forecast Funnel

XLSX
ForecastingNew product planning

Epidemiology to treated patients, each step sourced and rate-checked.

Prevalence
412,000
Diagnosed
321,000
Biomarker +
141,000
2L eligible
84,000
Treated
48,000
every rate cited low / base / high included

Competitive Landscape

PPTX · DOCX
Competitive intelligenceCommercial

Every asset by phase and line — with the white space stated, not implied.

Ph1
Ph2
Ph3
Mkt
1L
2L
2L+ combo
OPEN
OPEN
Western sponsor China-origin

Conference Coverage

PPTX debrief
Competitive intelligenceScientific & clinical

Sessions triaged against your assets while the congress is still running.

Day 2 · 41 abstracts screened live
LBA-04 · Ph3 comparator, 2L mPFS 11.4 mo — above your target bar
Poster 812 · China-origin asset First Western disclosure of Ph2 data
KOL panel · sequencing debate Two of four favour earlier use

Patient Segmentation

PPTX · XLSX
CommercialNew product planning

Segments defined on clinical evidence, sized against the funnel.

34%
27%
23%
16%
Biomarker-high, fit Highest value · 16k pts
Prior-IO exposed Unmet need · 13k pts
Comorbid / frail Tolerability-led · 11k pts
Community-treated Access-led · 8k pts

Deal Comparables

XLSX · PPTX
Search & evaluate · BD&LForecasting

Deal structure, not just headline biobucks — with the implied range.

Upfront Total deal value
Ph2 · A
$1.24B
Ph2 · B
$0.86B
Ph3 · C
$2.10B
Ph3 · D
$1.75B
implied upfront range $180–420M

Business Assessment

DOCX · PPTX · XLSX
Search & evaluate · BD&LCommercial

The whole opportunity case in one pack, section by section traceable.

1 · Opportunity framing 18 cites
2 · Competitive threat read 42 cites
3 · Revenue potential 27 cites
4 · Risk register 31 cites
Uncited claims 0

Name the deliverable. We’ll build the first draft live.

Request a demo